Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease
- 1 July 2002
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (1), 23-28
- https://doi.org/10.1038/sj.bmt.1703602
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001
- Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 yearsAmerican Journal of Hematology, 2000
- Veno-occlusive disease of the liverCurrent Opinion in Oncology, 2000
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factorsBone Marrow Transplantation, 1998
- Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcomaCancer, 1997
- Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liverHepatology, 1995
- Actinomycin D associated hepatic veno-occlusive disease — A report of 2 casesPathology, 1994
- Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 1993
- Hepatic Veno-Occlusive Disease Caused by 6-ThioguanineAnnals of Internal Medicine, 1982